🔴 Alzamend Neuro is trading 6% down today on an earnings preview projecting zero revenue and a $0.67 EPS loss

Alzamend Neuro is trading at $1.26 (-5.97%) as investors position themselves ahead of the company's July 28, 2026, earnings report.

• The Q2 2026 earnings preview forecasts zero revenue and an expected EPS loss of $0.67.
• The decline appears to be driven by company-specific positioning and profit-taking, as the broader biotech sector remains relatively firm.